

AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims

Claims 1 - 11 (Cancelled).

12. (Currently Amended) A process for treating a disease in a mammalian subject comprising administering to said subject an effective amount of an intermediary metabolite or a reagent that increases the intracellular or extracellular or serum level of a mammalian intermediary metabolite in said subject, said increases in the intracellular or extracellular or serum level of a mammalian intermediary metabolite resulting in a change in the immune profile of subject, wherein said intermediary metabolite is a glycolipid, and wherein said disease is cancer, a viral infection, or an autoimmune disease.

13. (Cancelled)

14. (Cancelled)

15. (Previously Presented) The process of claim 12, wherein said glycolipid comprises a monosaccharide ceramide.

16. (Previously Presented) The process of claim 15, wherein said monosaccharide ceramide comprises a glucosyl ceramide or galatosyl ceramide.

17. (Original) The process of claim 12, wherein said administering step is carried out by means comprising intravenous means, intramuscular means, subcutaneous means, intra-peritoneal means or oral means.

18. (Cancelled)

19. (Cancelled)

20. (Previously Presented) The process of claim 12, wherein said viral infection comprises HBV, HCV or HIV.

21. (Withdrawn) The process of claim 12, wherein said autoimmune disease comprises diabetes type I, diabetes type II, rheumatoid arthritis, Crohn's disease, arteriosclerosis and ulcerative colitis.

22. (Previously Presented) The process of claim 12, wherein said reagent increases the rate of production of said glycolipid in said subject.

23. (Previously Presented) The process of claim 12, wherein said reagent decreases the rate of degradation or turnover of said glycolipid in said subject.

24. (Previously Presented) The process of claim 12, wherein said mammalian subject is a human.

Claims 25-62 (Cancelled)

63. (Previously Presented) The process of claim 15, wherein the viral infection is an HCV infection.

64. (Previously Presented) The process of claim 16, wherein the viral infection is an HCV infection.